Alto Neuroscience reports strong cash position and advances clinical trials for neuropsychiatric treatments
Alto Neuroscience Inc. reported a cash balance of $184.2 million as of October 31, 2025, following the closing of a $50 million PIPE financing. Research and development expenses for the quarter ended September 30, 2025, were $10.5 million, down from $13.1 million in the same period in 2024. General and administrative expenses were $4.4 million, compared to $5.8 million a year earlier. The company reported a net loss of $14.2 million for the quarter, compared to $16.8 million in the prior year. Alto expects its current cash position to fund operations into 2028 and support the advancement of its clinical pipeline, including the planned initiation of a Phase 2b trial for ALTO-207 in the first half of 2026 and a Phase 3 trial by early 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112497891) on November 12, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。